Ivosidenib, Venetoclax, and Azacitidine for Hematologic Malignancies
Phase 1/2
96
about 9.5 years
18+
4 sites in MA, OH, OR +1
What this study is about
This trial is testing the safety and best dose of venetoclax when combined with ivosidenib and/or azacitidine in treating patients with IDH1-mutated hematologic malignancies. The goal is to determine if this combination treatment works better than venetoclax alone.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Azacitidine
- 2.Take Ivosidenib
- 3.Take Venetoclax
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
azacitidine, ivosidenib, venetoclax
injection, subcutaneous, oral (Oral Tablet), oral
Primary: Dose-limiting toxicity, Incidence of adverse events, Overall response rate (ORR)
Secondary: Duration of response, Event-free survival, Overall survival
Oncology